Nabriva Therapeutics plc Annual Share-based Payment Arrangement, Expense in USD from 2015 to 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Nabriva Therapeutics plc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2015 to 2022.
  • Nabriva Therapeutics plc Share-based Payment Arrangement, Expense for the quarter ending June 30, 2023 was $98K, a 70.7% decline year-over-year.
  • Nabriva Therapeutics plc Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2023 was $1.73M.
  • Nabriva Therapeutics plc annual Share-based Payment Arrangement, Expense for 2022 was $1.97M, a 40.2% decline from 2021.
  • Nabriva Therapeutics plc annual Share-based Payment Arrangement, Expense for 2021 was $3.29M, a 36.9% decline from 2020.
  • Nabriva Therapeutics plc annual Share-based Payment Arrangement, Expense for 2020 was $5.22M, unchanged from 2019.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 $1.97M -$1.32M -40.2% Jan 1, 2022 Dec 31, 2022 10-K 2023-04-17
2021 $3.29M -$1.93M -36.9% Jan 1, 2021 Dec 31, 2021 10-K 2023-04-17
2020 $5.22M $0 0% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-29
2019 $5.22M +$65K +1.26% Jan 1, 2019 Dec 31, 2019 10-K 2023-04-17
2018 $5.15M -$578K -10.1% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-11
2017 $5.73M +$3.19M +125% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-12
2016 $2.55M +$1.19M +88.4% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-12
2015 $1.35M Jan 1, 2015 Dec 31, 2015 10-K 2018-03-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.